文献速递消化与肝胆胰病理细胞病理与分子病理

EUS-FNA与FNB获取胰腺腺癌标本用于二代测序的充分性评估

Adequacy evaluation and use of pancreatic adenocarcinoma specimens for next-generation sequencing acquired by endoscopic ultrasound-guided FNA and FNB.
PubMed 文献 · Cancer Cytopathol · 2021-12-14

该回顾性研究纳入26例同时接受EUS-FNA和EUS-FNB取样的PDAC病例,评估标本对NGS和IHC的充分性。EUS-FNA涂片全部诊断PDAC,EUS-FNB细胞块77%诊断;81%涂片和42%细胞块满足NGS,9例双标本充分者行NGS检出KRAS、TP53和SMAD4突变。结论为两种方法均可提供NGS材料,FNA诊断率和NGS充分性更高,FNB更适合IHC。

要点

  • EUS-FNA涂片诊断PDAC的病例数高于EUS-FNB细胞块(26例 vs 20例)。
  • EUS-FNA涂片满足NGS的比例(81%)高于EUS-FNB细胞块(42%)。
  • EUS-FNB细胞块更适合基于IHC的生物标志物检测。

核心结论

  • EUS-FNA和EUS-FNB均可为PDAC的靶向NGS提供最佳材料。
  • 同时取样时EUS-FNA标本诊断率和NGS充分性高于EUS-FNB,而EUS-FNB更适合IHC检测。

研究设计与样本

  • 回顾性识别同时接受EUS-FNA和EUS-FNB取样的PDAC病例。
  • EUS-FNA标本制备涂片,EUS-FNB标本制备细胞块,所有病例行快速现场评估诊断充分性。
  • 评估NGS和IHC检测的标本充分性,对涂片和细胞块均满足NGS的病例行靶向NGS。
  • 共纳入26例PDAC病例。

主要发现

  • 26例EUS-FNA涂片均诊断PDAC,20例(77%)EUS-FNB细胞块诊断PDAC。
  • 9例涂片和细胞块均满足NGS的病例行NGS,检出KRAS、TP53和SMAD4等临床显著基因突变。

临床怎么用

  • PDAC患者需NGS检测时,EUS-FNA涂片可能提供更高诊断率和NGS充分性。
  • 需IHC生物标志物检测时,EUS-FNB细胞块可能更合适。
  • 同时行EUS-FNA和EUS-FNB可互补提高生物标志物检测成功率。

局限性

  • 回顾性研究,样本量较小(26例)。
  • NGS仅在9例双标本均满足要求的病例中进行。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Endoscopic ultrasound-guided tissue acquisition (EUS-TA), especially endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA), is the mainstay of tissue acquisition for the diagnosis of pancreatic ductal adenocarcinoma (PDAC). Recently, endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) using flexible biopsy needles has been used for patients with PDAC in an effort to increase diagnostic yields and biomarker testing. However, the role of EUS-TA in biomarker testing for personalized therapy or precise chemotherapy for PDAC is not well established. METHODS: PDAC cases with specimens acquired through concurrent EUS-FNA and EUS-FNB were identified retrospectively. Smears were prepared from EUS-FNA sampling, and cell blocks (CBs) were prepared from EUS-FNB sampling. Rapid onsite evaluation was conducted for all cases for diagnostic adequacy. The adequacy for biomarker testing, including next-generation sequencing (NGS) and immunohistochemistry (IHC) assays, was evaluated, and cases with smears and CBs adequate for NGS were processed for targeted NGS. RESULTS: There were 26 PDAC cases concurrently sampled by EUS-FNA and EUS-FNB. EUS-FNA smears for all 26 cases and EUS-FNB CBs for 20 cases (77%) were diagnostic for PDAC. Twenty-one smears (81%) and 11 CBs (42%) were adequate for NGS. Nine cases with both smears and CBs adequate for NGS underwent NGS, which identified clinically significant gene mutation variants, including KRAS, TP53, and SMAD4 mutations. CONCLUSIONS: Both EUS-FNA and EUS-FNB can provide optimal material for targeted NGS for PDACs. In PDAC cases subjected to concurrent EUS-FNA and EUS-FNB, EUS-FNA specimens had greater diagnostic yields and more adequate material for NGS than EUS-FNB specimens, whereas EUS-FNB was more suitable for IHC-based biomarker testing.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Gan Q, Roy-Chowdhuri S, Duose DY, et al. Adequacy evaluation and use of pancreatic adenocarcinoma specimens for next-generation sequencing acquired by endoscopic ultrasound-guided FNA and FNB. Cancer Cytopathol. 2021. PMID: 34905283. doi:10.1002/cncy.22533

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。